FindTrial
Sign In

Prevalence of Right Ventricular Dysfunction-Pulmonary Hypertension and Its Association with COVID-19 Clinical Outcome: A Meta-Analysis

Prevalence of Right Ventricular Dysfunction-Pulmonary Hypertension and Its Association with COVID-19 Clinical Outcome: A Meta-Analysis - Prevalence of Right Ventricular Dysfunction-Pulmonary Hypertension and Its Association with COVID-19 Clinical Outcome: A Meta-Analysis

Status
Active, not recruiting
Phases
Unknown
Study type
Unknown
Source
JPRN
Registry ID
JPRN-UMIN000042424
Enrollment
1000
Registered
2020-11-11
Start date
2020-11-11
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19

Interventions

None listed

Sponsors

Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: all observational studies or trials that involving adult patients with COVID-19 that had any data of right ventricular dysfunction and pulmonary arterial hypertension for comparison poor vs good outcome

Exclusion criteria

Exclusion criteria: missing required data, no data on RVD/ PAH, no outcome of interest, other than english language

Design outcomes

Primary

MeasureTime frame
Composite poor outcome of severity. mortality, need for ICU and mechanical ventilation—

Secondary

MeasureTime frame
each percentage of primary outcome: severity. mortality, need for ICU and mechanical ventilation—

Countries

Asia(except Japan)

Contacts

Public ContactEka Mulia

Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia Department of Cardiology and Vascular Medicine

eka.prasetya.budi-2017@fk.unair.ac.id628562765365

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026